We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

India offers many advantages for drug companies interested in conducting clinical trials. It has a large population of patients with common diseases that affect developing nations, but also has growing numbers of patients with so-called 'diseases of affluence'. Furthermore, many people have never taken drugs for their conditions, simplifying patient enrolment and management.

Several international clinical research organisations have already set up shop and are running projects for European and US clients. But, reports Dinesh Sharma in this article, industry representatives say that India needs to relax its rules governing clinical trials to take advantage of its position.

Critics, however, say that India is not ready for looser regulation. And an expert review panel recently concluded that the government needed to be even more aggressive in its control of clinical trials in the country.

Link to full article in The Lancet*

* Free registration is required to view this article

Reference: The Lancet 363, 9420 (2004)

Related topics